{
  "$schema": "folio-library-document/v1",
  "id": "10665-331170",
  "title": "WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment",
  "variant": "pdf",
  "pages": 56,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Table of Contents",
      "number": null,
      "page": 5,
      "pageLabel": "iii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-table-of-contents"
    },
    {
      "level": 2,
      "title": "Acknowledgements",
      "number": null,
      "page": 6,
      "pageLabel": "iv",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-acknowledgements"
    },
    {
      "level": 2,
      "title": "Abbreviations & acronyms",
      "number": null,
      "page": 8,
      "pageLabel": "vi",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-abbreviations-acronyms"
    },
    {
      "level": 2,
      "title": "Definitions",
      "number": null,
      "page": 9,
      "pageLabel": "vii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-definitions"
    },
    {
      "level": 2,
      "title": "Executive summary",
      "number": null,
      "page": 10,
      "pageLabel": "viii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-executive-summary"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": null,
      "page": 14,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-introduction"
    },
    {
      "level": 3,
      "title": "Background",
      "number": "1",
      "page": 14,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-1-background"
    },
    {
      "level": 3,
      "title": "Rationale",
      "number": "2",
      "page": 14,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-2-rationale"
    },
    {
      "level": 3,
      "title": "Scope of the current update",
      "number": "3",
      "page": 15,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-3-scope-of-the-current-update"
    },
    {
      "level": 3,
      "title": "Target audience",
      "number": "4",
      "page": 15,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-4-target-audience"
    },
    {
      "level": 2,
      "title": "Recommendations",
      "number": "1",
      "page": 16,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-1-recommendations"
    },
    {
      "level": 2,
      "title": "Monitoring and evaluation",
      "number": "2",
      "page": 39,
      "pageLabel": "26",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-2-monitoring-and-evaluation"
    },
    {
      "level": 2,
      "title": "Research gaps",
      "number": "3",
      "page": 41,
      "pageLabel": "28",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-3-research-gaps"
    },
    {
      "level": 2,
      "title": "References",
      "number": "4",
      "page": 44,
      "pageLabel": "31",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-4-references"
    },
    {
      "level": 2,
      "title": "Supplementary Table",
      "number": null,
      "page": 51,
      "pageLabel": "38",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-supplementary-table"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 5,
      "labelStart": "a",
      "labelEnd": "iii",
      "words": 524,
      "summary": {
        "text": "The title, copyright, licence and cataloguing pages of the WHO consolidated guidelines on tuberculosis, Module 1: prevention, on TB preventive treatment (2020), with ISBNs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis preventive",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "prevention tuberculosis",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        }
      ],
      "extract": "WHO consolidated guidelines on tuberculosis Module 1: Prevention Tuberculosis preventive treatment © World Health Organization 2020 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for",
      "extractCut": true,
      "blocks": [
        "library/10665-331170/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-table-of-contents",
      "number": null,
      "title": "Table of Contents",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 6,
      "labelStart": "iii",
      "labelEnd": "iv",
      "words": 53,
      "summary": {
        "text": "The table of contents of the 2020 WHO guidelines on TB preventive treatment, listing chapters and online annexes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "panels",
          "heading": false
        },
        {
          "term": "tables",
          "heading": false
        },
        {
          "term": "grade",
          "heading": false
        }
      ],
      "extract": "Acknowledgements\b iv Abbreviations & acronyms\b vi Definitions\b vii Executive summary\b viii Introduction\b 1 1. Recommendations\b 3 2. Monitoring and evaluation\b 26 3. Research gaps\b 28 4. References\b 31 Supplementary Table\b 38 Online annexes Annex 1. Methods and Expert panels Annex 2. GRADE Summary of Evidence Tables Annex 3. GRADE Evidence to Decision Tables",
      "extractCut": false
    },
    {
      "id": "sec-001-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 2,
      "pageStart": 6,
      "pageEnd": 8,
      "labelStart": "iv",
      "labelEnd": "vi",
      "words": 819,
      "summary": {
        "text": "Acknowledges the WHO Global TB Programme staff who coordinated the guidelines and lists the members of the Guideline Development Group and other contributors. It also thanks the Guideline Review Committee and names USAID and the Russian Federation as funders of the 2019–2020 update. The names and affiliations come from many countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nandi siegfried",
          "heading": false
        },
        {
          "term": "lindiwe mvusi",
          "heading": false
        },
        {
          "term": "avinash kanchar",
          "heading": false
        },
        {
          "term": "carmen figueroa",
          "heading": false
        },
        {
          "term": "matteo zignol",
          "heading": false
        },
        {
          "term": "yohhei hamada",
          "heading": false
        },
        {
          "term": "hopkins university",
          "heading": false
        },
        {
          "term": "collaborating centre",
          "heading": false
        }
      ],
      "extract": "The production of the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment was coordinated and written by Dennis Falzon, Avinash Kanchar and Matteo Zignol under the overall direction of Tereza Kasaeva, Director of the WHO Global TB Programme. The WHO Global TB Programme gratefully acknowledges the contribution of all experts involved in the production of these guidelines.1 Guideline",
      "extractCut": true
    },
    {
      "id": "sec-002-abbreviations-acronyms",
      "number": null,
      "title": "Abbreviations & acronyms",
      "level": 2,
      "pageStart": 8,
      "pageEnd": 9,
      "labelStart": "vi",
      "labelEnd": "vii",
      "words": 139,
      "summary": {
        "text": "A list of abbreviations and acronyms used in the TB preventive treatment guidelines, including regimen codes such as 3HP and 1HP.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "isoniazid monotherapy",
          "heading": false
        },
        {
          "term": "plus isoniazid",
          "heading": false
        },
        {
          "term": "rifapentine plus",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "months",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        }
      ],
      "extract": "1HP One month of daily rifapentine plus isoniazid 3HP Three months of weekly rifapentine plus isoniazid 3HR Three months of daily rifampicin plus isoniazid 4R Four months of daily rifampicin monotherapy 6H Six months of daily isoniazid monotherapy 9H Nine months of daily isoniazid monotherapy ART antiretroviral treatment BCG bacille Calmette-Guérin (vaccine) CI confidence interval ERG External Review Group GDG",
      "extractCut": true
    },
    {
      "id": "sec-003-definitions",
      "number": null,
      "title": "Definitions",
      "level": 2,
      "pageStart": 9,
      "pageEnd": 10,
      "labelStart": "vii",
      "labelEnd": "viii",
      "words": 500,
      "summary": {
        "text": "Defines terms used in the TB preventive treatment guidelines, such as age groups, contact investigation, household contact and high TB transmission setting. It also defines TB disease as distinct from TB infection and underweight in adults and children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "contact investigation",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "index case",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "definitions",
          "heading": true
        },
        {
          "term": "person",
          "heading": false
        },
        {
          "term": "ltbi",
          "heading": false
        },
        {
          "term": "undiagnosed",
          "heading": false
        }
      ],
      "extract": "Definitions Note: The definitions listed below apply to the terms as used in these guidelines. They may have different meanings in other contexts. Adolescent: A person aged 10–19 years Adult: A person over 19 years of age Bacteriologically confirmed TB: TB diagnosed in a biological specimen by smear microscopy, culture or a WHO-approved molecular test such as Xpert® MTB/RIF Child: A person under 10 years of age",
      "extractCut": true
    },
    {
      "id": "sec-004-executive-summary",
      "number": null,
      "title": "Executive summary",
      "level": 2,
      "pageStart": 10,
      "pageEnd": 14,
      "labelStart": "viii",
      "labelEnd": "1",
      "words": 1892,
      "summary": {
        "text": "The executive summary of the 2020 guidelines, defining latent TB infection, noting that about a quarter of the world's population is infected, and placing preventive treatment within the End TB Strategy. It describes the intended users and the aims of the update. It lists the main changes, including recommendations reworded to apply regardless of TB burden, adding 1-month rifapentine plus isoniazid and 4-month rifampicin as options in all settings, and simplified regimen durations. It also notes that a single algorithm replaces four earlier ones and that references and research gaps were updated.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "isoniazid preventive",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "offered preventive",
          "heading": false
        },
        {
          "term": "ltbi testing",
          "heading": false
        },
        {
          "term": "tuberculosis preventive",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "systematic ltbi",
          "heading": false
        },
        {
          "term": "treatment options",
          "heading": false
        }
      ],
      "extract": "Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by M. tuberculosis antigens with no evidence of clinically manifest active TB. It is estimated that about a quarter of the world’s population is infected with TB. TB preventive treatment (TPT) is one of the key interventions recommended by WHO to achieve the End TB Strategy targets, as upheld by the UN High Level",
      "extractCut": true
    },
    {
      "id": "sec-005-introduction",
      "number": null,
      "title": "Introduction",
      "level": 2,
      "pageStart": 14,
      "pageEnd": 14,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-006-1-background",
      "number": "1",
      "title": "Background",
      "level": 3,
      "pageStart": 14,
      "pageEnd": 14,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 432,
      "summary": {
        "text": "Gives background on latent TB infection, noting that 5–10% of those infected develop active disease, usually within five years, and that immune status is the main risk factor. It recalls the 2018 UN high-level meeting commitment to provide preventive treatment to 30 million people by 2022 and places it within the End TB Strategy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "million people",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "active",
          "heading": false
        },
        {
          "term": "pmtpt",
          "heading": false
        },
        {
          "term": "ltbi",
          "heading": false
        },
        {
          "term": "disease",
          "heading": false
        }
      ],
      "extract": "Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by M. tuberculosis antigens with no evidence of clinically manifest active TB (1)3. As there is no “gold standard” test for TB infection, the global burden is not known with certainty; however, about one fourth of the world’s population is estimated to be infected with M. tuberculosis (2),(3). The vast majority",
      "extractCut": true
    },
    {
      "id": "sec-007-2-rationale",
      "number": "2",
      "title": "Rationale",
      "level": 3,
      "pageStart": 14,
      "pageEnd": 15,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 237,
      "summary": {
        "text": "Explains the rationale for the guidelines, which weigh risk of progression, TB burden, feasibility and public health impact and are meant to be adapted nationally. It notes low global coverage and that new evidence since the 2018 consolidated guidelines required revisiting some recommendations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "risk groups",
          "heading": false
        },
        {
          "term": "ltbi",
          "heading": false
        },
        {
          "term": "latent",
          "heading": false
        },
        {
          "term": "guidelines",
          "heading": false
        },
        {
          "term": "contacts",
          "heading": false
        },
        {
          "term": "condition",
          "heading": false
        },
        {
          "term": "infection",
          "heading": false
        }
      ],
      "extract": "WHO guidelines on PMTPT are premised upon the probability that the condition will progress to active TB disease in specific risk groups, on the underlying epidemiology and burden of TB, the feasibility of the intervention, and the likelihood of a broader public health impact. They are expected to provide the basis for the development of national guidelines for LTBI management, adapted to the local circumstances.",
      "extractCut": true
    },
    {
      "id": "sec-008-3-scope-of-the-current-update",
      "number": "3",
      "title": "Scope of the current update",
      "level": 3,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 287,
      "summary": {
        "text": "Describes the scope of the update, which addressed three PICO questions on 4-month rifampicin, 1-month rifapentine plus isoniazid, and isoniazid safety in pregnant and postpartum women. It notes that wording was clarified and that the earlier distinction between high- and low-incidence settings was reconsidered, with evidence judged using GRADE evidence-to-decision criteria.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "current update",
          "heading": true
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "treatment regimens",
          "heading": false
        },
        {
          "term": "pico",
          "heading": false
        },
        {
          "term": "disease compared",
          "heading": false
        },
        {
          "term": "wording",
          "heading": false
        },
        {
          "term": "ages",
          "heading": false
        },
        {
          "term": "threshold",
          "heading": false
        }
      ],
      "extract": "The current update considered evidence for three questions, worded in PICO format4, namely: • In people of all ages at risk of active TB, does a 4-month daily rifampicin regimen safely prevent TB disease compared to other recommended TB preventive treatment regimens? (PICO 6) • In people of all ages at risk of active TB, does a 1-month daily rifapentine plus isoniazid regimen safely prevent TB disease compared to",
      "extractCut": true
    },
    {
      "id": "sec-009-4-target-audience",
      "number": "4",
      "title": "Target audience",
      "level": 3,
      "pageStart": 15,
      "pageEnd": 16,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 203,
      "summary": {
        "text": "Identifies the target audience as national TB, HIV and maternal and child health programmes and other policy-makers, staff of agencies such as prison and immigration services, and clinicians in public and private sectors.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infectious diseases",
          "heading": false
        },
        {
          "term": "picos",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "child health",
          "heading": false
        },
        {
          "term": "ministries",
          "heading": false
        },
        {
          "term": "guidelines",
          "heading": false
        }
      ],
      "extract": "The WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment provides a comprehensive set of recommendations for PMTPT geared towards the implementers of the WHO End TB Strategy and also for countries intent upon TB elimination (9). The guidelines are to be used primarily in national TB and HIV and maternal and child programmes or their equivalents in ministries of health and for other",
      "extractCut": true
    },
    {
      "id": "sec-010-1-recommendations",
      "number": "1",
      "title": "Recommendations",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 39,
      "labelStart": "3",
      "labelEnd": "26",
      "words": 13542,
      "summary": {
        "text": "The main recommendations chapter of the 2020 TB preventive treatment guidelines, which begins by explaining why preventive treatment should target groups at highest risk of progression. It gives recommendations and supporting evidence for adults, adolescents, infants and children living with HIV, citing trial data on reduced TB risk and added benefit alongside antiretroviral therapy. The chapter goes on to cover other risk groups, testing and treatment options across a long, cut section. It ends with preventive treatment for contacts of people with multidrug-resistant TB, advising individualized fluoroquinolone-based regimens and written informed consent given very low-certainty evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "isoniazid preventive",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "mdr-tb preventive",
          "heading": false
        },
        {
          "term": "systematic ltbi",
          "heading": false
        },
        {
          "term": "ltbi status",
          "heading": false
        },
        {
          "term": "ltbi testing",
          "heading": false
        },
        {
          "term": "ltbi tests",
          "heading": false
        },
        {
          "term": "baseline ltbi",
          "heading": false
        }
      ],
      "extract": "1.1. Identification of populations for testing of latent tuberculosis infection and TB preventive treatment Among individuals infected with M. tuberculosis it is estimated that the lifetime risk of progressing to active TB averages to about 5–10% (4). The risk is particularly elevated among children under the age of 5 years and among people with compromised immunity (1). As any treatment entails risk of harms and",
      "extractCut": true
    },
    {
      "id": "sec-011-2-monitoring-and-evaluation",
      "number": "2",
      "title": "Monitoring and evaluation",
      "level": 2,
      "pageStart": 39,
      "pageEnd": 41,
      "labelStart": "26",
      "labelEnd": "28",
      "words": 871,
      "summary": {
        "text": "Describes monitoring and evaluation of programmatic TB preventive treatment, including core indicators, national recording and reporting systems and involving the private sector. It covers adverse drug reactions, monthly follow-up, warning symptoms of hepatotoxicity and when baseline liver testing is advised. It ends with clinical follow-up of contacts exposed to multidrug-resistant TB for at least two years and attention to drug interactions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "mdr-tb preventive",
          "heading": false
        },
        {
          "term": "adverse reactions",
          "heading": false
        },
        {
          "term": "liver disease",
          "heading": false
        },
        {
          "term": "liver function",
          "heading": false
        },
        {
          "term": "ltbi care",
          "heading": false
        },
        {
          "term": "monitoring",
          "heading": true
        },
        {
          "term": "adverse events",
          "heading": false
        }
      ],
      "extract": "2. Monitoring and evaluation Coverage of contact investigation and TB preventive treatment among child contacts and PLHIV are among the top 10 core indicators for monitoring implementation of the End TB Strategy (8). National TB and HIV programmes report data yearly to WHO and UNAIDS on progress in LTBI care in target populations. PMTPT should include monitoring and evaluation systems that are aligned with national",
      "extractCut": true
    },
    {
      "id": "sec-012-3-research-gaps",
      "number": "3",
      "title": "Research gaps",
      "level": 2,
      "pageStart": 41,
      "pageEnd": 44,
      "labelStart": "28",
      "labelEnd": "31",
      "words": 1109,
      "summary": {
        "text": "Sets out research gaps in TB preventive treatment, including risk of progression in groups such as people with diabetes or who smoke, and better algorithms for ruling out active TB. It calls for improved diagnostic tests for infection and shorter, better-tolerated regimens, with more data on rifapentine in young children and pregnancy. It also lists needs on implementation, contact tracing strategies and monitoring tools.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "research gaps",
          "heading": true
        },
        {
          "term": "ltbi regimens",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "different ltbi",
          "heading": false
        },
        {
          "term": "ltbi tests",
          "heading": false
        },
        {
          "term": "at-risk populations",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "clinical studies",
          "heading": false
        }
      ],
      "extract": "3. Research gaps The evidence reviewed ahead of the current update exposed additional knowledge gaps to the ones reported in other recent updates of the guidelines. Continued research on development and on implementation science remain critical for many aspects of the PMTPT. Some of this information may be collected as part of user feedback put in place by the implementing programme. Risks for progression to active",
      "extractCut": true
    },
    {
      "id": "sec-013-4-references",
      "number": "4",
      "title": "References",
      "level": 2,
      "pageStart": 44,
      "pageEnd": 51,
      "labelStart": "31",
      "labelEnd": "38",
      "words": 3366,
      "summary": {
        "text": "The reference list for the TB preventive treatment guidelines, with over 100 citations to journal studies and WHO and UN documents on TB infection, treatment and policy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "latent tuberculosis",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "lung dis",
          "heading": false
        },
        {
          "term": "isoniazid preventive",
          "heading": false
        },
        {
          "term": "cited aug",
          "heading": false
        },
        {
          "term": "tuberc lung",
          "heading": false
        },
        {
          "term": "engl med",
          "heading": false
        },
        {
          "term": "latent tuberculous",
          "heading": false
        }
      ],
      "extract": "1. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis Infection. N Engl J Med. 2015 May 28;372(22):2127–35. 2. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health. 2014 Aug;2(8):e453–9. 3. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation",
      "extractCut": true
    },
    {
      "id": "sec-014-supplementary-table",
      "number": null,
      "title": "Supplementary Table",
      "level": 2,
      "pageStart": 51,
      "pageEnd": 56,
      "labelStart": "38",
      "labelEnd": "43",
      "words": 2086,
      "summary": {
        "text": "A supplementary table comparing WHO's 2018 recommendations on tuberculosis preventive treatment with those in the current update, section by section. A note explains that two LTBI testing recommendations became implementation remarks and that four regimen recommendations were merged into one. Each row pairs the old and new wording for groups such as people living with HIV, infants and children, and household contacts, marking whether changes were language edits or substantive. It closes with the recommendation on 36 months of isoniazid in high-transmission settings and WHO Global TB Programme contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "isoniazid preventive",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "offered preventive",
          "heading": false
        },
        {
          "term": "ltbi testing",
          "heading": false
        },
        {
          "term": "isoniazid monotherapy",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "language editing",
          "heading": false
        },
        {
          "term": "contacts aged",
          "heading": false
        }
      ],
      "extract": "Supplementary Table Summary of changes to the WHO TB preventive treatment recommendations between 2018 and current updates Note: In the current update, two of the 2018 recommendations on LTBI testing (Section C) were incorporated into the remarks as implementation considerations; four recommendations on individual TB preventive treatment options have been merged into one recommendation (Recommendation 17).",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 4,
        "items": [
          "1 Background",
          "2 Rationale",
          "3 Scope of the current update",
          "4 Target audience"
        ]
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "preventive treatment",
      "heading": true
    },
    {
      "term": "isoniazid preventive",
      "heading": false
    },
    {
      "term": "tuberculosis preventive",
      "heading": false
    },
    {
      "term": "mdr-tb preventive",
      "heading": false
    },
    {
      "term": "offered preventive",
      "heading": false
    },
    {
      "term": "preventive therapy",
      "heading": false
    },
    {
      "term": "ltbi regimens",
      "heading": false
    },
    {
      "term": "initiating preventive",
      "heading": false
    },
    {
      "term": "ltbi testing",
      "heading": false
    },
    {
      "term": "ltbi regardless",
      "heading": false
    },
    {
      "term": "different preventive",
      "heading": false
    },
    {
      "term": "active tuberculosis",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "a",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "b",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "x",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "xi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 14,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 15,
      "label": "2",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "3",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 17,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 19,
      "label": "6",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 20,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "8",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 22,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 23,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "12",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "14",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 28,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "16",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "18",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "20",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "22",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "24",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "26",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 40,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 41,
      "label": "28",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 42,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "30",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 44,
      "label": "31",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 45,
      "label": "32",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 46,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 47,
      "label": "34",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 48,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 49,
      "label": "36",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 50,
      "label": "37",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 51,
      "label": "38",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 52,
      "label": "39",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "40",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 54,
      "label": "41",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 55,
      "label": "42",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 56,
      "label": "43",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "table",
      "number": "1",
      "title": "Recommendations in the WHO consolidated guidelines on tuberculosis:",
      "page": 11,
      "pageLabel": "ix",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "Pooled estimates of risk for active TB among household contacts",
      "page": 19,
      "pageLabel": "6",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "Recommended dosages of medicines for TB preventive treatment",
      "page": 36,
      "pageLabel": "23",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "vfig-p028",
      "file": "figures/vfig-p028.webp",
      "page": 28,
      "shows": [
        "Figure 1"
      ],
      "narratives": {
        "en": "Flowchart (printed rotated 90°) of the algorithm for LTBI testing and TB preventive treatment in individuals at risk (Fig. 1), with three entry groups: HIV positive, household contact and other risk group. People living with HIV with any symptom (current cough, fever, weight loss or night sweats), and symptomatic household contacts, are investigated for active TB; household contacts aged 5 years and over and other risk groups go to TST or IGRA, and if positive or unavailable to chest X-ray, with an abnormal result leading to investigation for active TB. Those without active TB are assessed for contraindications to preventive treatment, which is then given or deferred, with follow-up for active TB as necessary even after completing preventive treatment.",
        "ar": "مخطط انسيابي (مطبوع بدوران 90 درجة) للخوارزمية الخاصة باختبار عدوى السل الكامنة والعلاج الوقائي من السل لدى الأفراد المعرضين للخطر (الشكل 1)، مع ثلاث مجموعات دخول: المصابون بفيروس العوز المناعي البشري، والمخالطون المنزليون، وفئات الخطر الأخرى. ويُفحص المتعايشون مع فيروس العوز المناعي البشري الذين لديهم أي عرض (سعال حالي أو حمى أو فقدان الوزن أو تعرق ليلي)، والمخالطون المنزليون الذين تظهر عليهم أعراض، للكشف عن السل النشط؛ ويخضع المخالطون المنزليون في سن 5 سنوات فأكثر وفئات الخطر الأخرى لاختبار التوبركولين الجلدي أو اختبار إطلاق الإنترفيرون غاما، وإذا كانت النتيجة إيجابية أو لم يتوفر الاختبار يُجرى تصوير الصدر بالأشعة السينية، وتؤدي النتيجة غير الطبيعية إلى الفحص للكشف عن السل النشط. ويُقيَّم من ليس لديهم سل نشط بحثاً عن موانع العلاج الوقائي، الذي يُعطى بعد ذلك أو يُؤجَّل، مع المتابعة للكشف عن السل النشط حسب الضرورة حتى بعد إكمال العلاج الوقائي.",
        "zh": "高危人群潜伏性结核感染检测和结核病预防性治疗算法流程图（图1，印刷时旋转了90°），包括三个入口人群：艾滋病毒阳性者、家庭接触者和其他高危人群。有任何症状（当前咳嗽、发热、体重减轻或盗汗）的艾滋病毒感染者以及有症状的家庭接触者接受活动性结核病检查；5岁及以上的家庭接触者和其他高危人群接受结核菌素皮肤试验或γ干扰素释放试验，如结果阳性或无法检测则进行胸部X线检查，结果异常者接受活动性结核病检查。无活动性结核病者评估是否存在预防性治疗禁忌证，随后给予或推迟预防性治疗；必要时随访活动性结核病，即使已完成预防性治疗。",
        "es": "Diagrama de flujo (impreso girado 90°) del algoritmo para la prueba de la ITBL y el tratamiento preventivo de la tuberculosis en personas en riesgo (fig. 1), con tres grupos de entrada: VIH positivo, contacto domiciliario y otro grupo de riesgo. Las personas con el VIH que presentan algún síntoma (tos actual, fiebre, pérdida de peso o sudores nocturnos) y los contactos domiciliarios sintomáticos se investigan para descartar tuberculosis activa; los contactos domiciliarios de 5 años o más y otros grupos de riesgo pasan a la PCT o el IGRA y, si el resultado es positivo o no se dispone de la prueba, a la radiografía de tórax; un resultado anormal conduce a la investigación de tuberculosis activa. En quienes no tienen tuberculosis activa se evalúan las contraindicaciones del tratamiento preventivo, que luego se administra o se aplaza, con seguimiento para detectar tuberculosis activa según sea necesario incluso tras completar el tratamiento preventivo.",
        "fr": "Logigramme (imprimé avec une rotation de 90°) de l'algorithme de dépistage de l'infection tuberculeuse latente et de traitement préventif de la tuberculose chez les personnes à risque (fig. 1), avec trois groupes d'entrée : personnes séropositives pour le VIH, contacts familiaux et autres groupes à risque. Les personnes vivant avec le VIH présentant un symptôme (toux actuelle, fièvre, perte de poids ou sueurs nocturnes) et les contacts familiaux symptomatiques font l'objet d'une recherche de tuberculose active ; les contacts familiaux âgés de 5 ans et plus et les autres groupes à risque passent un TCT ou un IGRA puis, si le résultat est positif ou le test indisponible, une radiographie thoracique, un résultat anormal conduisant à une recherche de tuberculose active. Chez les personnes sans tuberculose active, on vérifie les contre-indications au traitement préventif, qui est alors administré ou différé, avec un suivi de la tuberculose active si nécessaire, même après la fin du traitement préventif.",
        "ru": "Блок-схема (напечатана с поворотом на 90°) алгоритма тестирования на ЛТБИ и профилактического лечения ТБ у лиц из групп риска (рис. 1) с тремя исходными группами: ВИЧ-положительные, контакты в домохозяйствах и другие группы риска. Люди, живущие с ВИЧ, с любым симптомом (текущий кашель, лихорадка, потеря массы тела или ночная потливость), а также контакты в домохозяйствах с симптомами обследуются на активный ТБ; контакты в домохозяйствах в возрасте 5 лет и старше и другие группы риска проходят ТКП или IGRA, а при положительном результате или недоступности теста — рентгенографию грудной клетки, причем отклонения от нормы ведут к обследованию на активный ТБ. У лиц без активного ТБ оцениваются противопоказания к профилактическому лечению, которое затем назначается или откладывается; при необходимости проводится наблюдение на предмет активного ТБ даже после завершения профилактического лечения."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment²",
      "pages": [
        11,
        12
      ],
      "columns": [
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "1.1. Identifying populations for LTBI testing and TB preventive treatment"
        ],
        [
          "People living with HIV"
        ],
        [
          "1. Adults and adolescents living with HIV who are unlikely to have active TB should receive TB preventive treatment as part of a comprehensive package of HIV care. Treatment should also be given to those on antiretroviral treatment, to pregnant women and to those who have previously been treated for TB, irrespective of the degree of immunosuppression and even if LTBI testing is unavailable."
        ],
        [
          "2. Infants aged < 12 months living with HIV who are in contact with a person with TB and who are unlikely to have active TB on an appropriate clinical evaluation or according to national guidelines should receive TB preventive treatment."
        ],
        [
          "3. Children aged ≥ 12 months living with HIV who are considered unlikely to have active TB on an appropriate clinical evaluation or according to national guidelines should be offered TB preventive treatment as part of a comprehensive package of HIV prevention and care if they live in a setting with high TB transmission, regardless of contact with TB."
        ],
        [
          "4. All children living with HIV who have successfully completed treatment for TB disease may receive TB preventive treatment."
        ],
        [
          "Household contacts (regardless of HIV status)"
        ],
        [
          "5. Children aged < 5 years who are household contacts of people with bacteriologically confirmed pulmonary TB and who are found not to have active TB on an appropriate clinical evaluation or according to national guidelines should be given TB preventive treatment even if LTBI testing is unavailable."
        ],
        [
          "6. Children aged ≥ 5 years, adolescents and adults who are household contacts of people with bacteriologically confirmed pulmonary TB who are found not to have active TB by an appropriate clinical evaluation or according to national guidelines may be given TB preventive treatment."
        ],
        [
          "7. In selected high-risk household contacts of patients with multidrug-resistant tuberculosis, preventive treatment may be considered based on individualized risk assessment and a sound clinical justification."
        ],
        [
          "Other people at risk"
        ],
        [
          "8. People who are initiating anti-TNF treatment, or receiving dialysis, or preparing for an organ or haematological transplant, or who have silicosis should be systematically tested and treated for LTBI."
        ],
        [
          "9. Systematic LTBI testing and treatment may be considered for prisoners, health workers, immigrants from countries with a high TB burden, homeless people and people who use drugs."
        ],
        [
          "10. Systematic LTBI testing and treatment is not recommended for people with diabetes, people who engage in the harmful use of alcohol, tobacco smokers and underweight people unless they also belong to other risk groups included in the above recommendations."
        ],
        [
          "1.2. Algorithms to rule out active TB disease"
        ],
        [
          "11. Adults and adolescents living with HIV should be screened for TB according to a clinical algorithm. Those who do not report any of the symptoms of current cough, fever, weight loss or night sweats are unlikely to have active TB and should be offered preventive treatment, regardless of their ART status."
        ],
        [
          "12. Adults and adolescents living with HIV who are screened for TB according to a clinical algorithm and who report any of the symptoms of current cough, fever, weight loss or night sweats may have active TB and should be evaluated for TB and other diseases and offered preventive treatment if active TB is excluded."
        ],
        [
          "13. Chest radiography may be offered to people living with HIV on ART and preventive treatment given to those with no abnormal radiographic findings."
        ],
        [
          "14. Infants and children living with HIV who have poor weight gain, fever or current cough or who have a history of contact with a person with TB should be evaluated for TB and other diseases that cause such symptoms. If TB disease is excluded after an appropriate clinical evaluation or according to national guidelines, these children should be offered TB preventive treatment, regardless of their age."
        ],
        [
          "15. The absence of any symptoms of TB and the absence of abnormal chest radiographic findings may be used to rule out active TB disease among HIV-negative household contacts aged ≥ 5 years and other risk groups before preventive treatment."
        ],
        [
          "1.3. Testing for LTBI"
        ],
        [
          "16. Either a tuberculin skin test (TST) or interferon-gamma release assay (IGRA) can be used to test for LTBI."
        ],
        [
          "1.4. TB preventive treatment options"
        ],
        [
          "17. The following options are recommended for the treatment of LTBI regardless of HIV status: 6 or 9 months of daily isoniazid, or a 3-month regimen of weekly rifapentine plus isoniazid, or a 3 month regimen of daily isoniazid plus rifampicin. A 1-month regimen of daily rifapentine plus isoniazid or 4 months of daily rifampicin alone may also be offered as alternatives."
        ],
        [
          "18. In settings with high TB transmission, adults and adolescents living with HIV who have an unknown or a positive LTBI test and are unlikely to have active TB disease should receive at least 36 months of daily isoniazid preventive therapy (IPT). Daily IPT for 36 months should be given whether or not the person is on ART, and irrespective of the degree of immunosuppression, history of previous TB treatment and pregnancy in settings considered to have a high TB transmission as defined by national authorities."
        ]
      ],
      "notes": "² The recommendations in the current update are compared with those in the 2018 guidelines in the Supplementary Table. [Transcriber: single-column table; section headings (1.1–1.4) and population subheadings are kept as rows, followed by the numbered recommendations.]",
      "narratives": {
        "en": "The table lists the 18 recommendations of the WHO consolidated guidelines on tuberculosis preventive treatment, grouped into four sections: identifying populations for LTBI testing and TB preventive treatment (people living with HIV, household contacts, other people at risk), algorithms to rule out active TB disease, testing for LTBI, and TB preventive treatment options.",
        "ar": "يسرد الجدول التوصيات الثماني عشرة الواردة في المبادئ التوجيهية الموحدة لمنظمة الصحة العالمية بشأن العلاج الوقائي من السل، مصنفة في أربعة أقسام: تحديد الفئات السكانية المستهدفة باختبار عدوى السل الكامنة والعلاج الوقائي من السل (المتعايشون مع فيروس العوز المناعي البشري، والمخالطون المنزليون، وغيرهم من المعرضين للخطر)، والخوارزميات المستخدمة لاستبعاد مرض السل النشط، واختبار عدوى السل الكامنة، وخيارات العلاج الوقائي من السل.",
        "zh": "本表列出世卫组织结核病综合指南中有关结核病预防性治疗的18项建议，分为四个部分：确定需进行潜伏性结核感染检测和结核病预防性治疗的人群（艾滋病毒感染者、家庭接触者、其他高危人群）、排除活动性结核病的算法、潜伏性结核感染检测，以及结核病预防性治疗方案。",
        "es": "El cuadro enumera las 18 recomendaciones de las directrices unificadas de la OMS sobre el tratamiento preventivo de la tuberculosis, agrupadas en cuatro secciones: identificación de las poblaciones para las pruebas de infección tuberculosa latente y el tratamiento preventivo (personas con el VIH, contactos domiciliarios, otras personas en riesgo), algoritmos para descartar la tuberculosis activa, pruebas de infección tuberculosa latente y opciones de tratamiento preventivo.",
        "fr": "Le tableau présente les 18 recommandations des lignes directrices unifiées de l’OMS sur le traitement préventif de la tuberculose, regroupées en quatre sections : identification des populations à soumettre au dépistage de l’infection tuberculeuse latente et au traitement préventif (personnes vivant avec le VIH, contacts familiaux, autres personnes à risque), algorithmes pour exclure une tuberculose évolutive, dépistage de l’infection tuberculeuse latente et options de traitement préventif.",
        "ru": "В таблице перечислены 18 рекомендаций сводного руководства ВОЗ по профилактическому лечению туберкулеза, сгруппированные в четыре раздела: определение групп населения для обследования на латентную туберкулезную инфекцию и профилактического лечения (люди, живущие с ВИЧ, бытовые контакты, другие группы риска), алгоритмы исключения активного туберкулеза, обследование на латентную туберкулезную инфекцию и варианты профилактического лечения."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2. Pooled estimates of risk for active TB among household contacts stratified by age and baseline LTBI status as compared with the general population",
      "pages": [
        19
      ],
      "columns": [
        {
          "titles": "Age (years)"
        },
        {
          "titles": "No. of studies",
          "group": "LTBI-positive at baseline – Follow-up < 12 months"
        },
        {
          "titles": "Risk ratio",
          "group": "LTBI-positive at baseline – Follow-up < 12 months"
        },
        {
          "titles": "No. of studies",
          "group": "LTBI-positive at baseline – Follow-up < 24 months"
        },
        {
          "titles": "Risk ratio",
          "group": "LTBI-positive at baseline – Follow-up < 24 months"
        },
        {
          "titles": "No. of studies",
          "group": "Regardless of baseline LTBI status – Follow-up < 12 months"
        },
        {
          "titles": "Risk ratio",
          "group": "Regardless of baseline LTBI status – Follow-up < 12 months"
        },
        {
          "titles": "No. of studies",
          "group": "Regardless of baseline LTBI status – Follow-up < 24 months"
        },
        {
          "titles": "Risk ratio",
          "group": "Regardless of baseline LTBI status – Follow-up < 24 months"
        }
      ],
      "rows": [
        [
          "General population",
          "–",
          "1.0 (reference)",
          "–",
          "1.0 (reference)",
          "–",
          "1.0 (reference)",
          "–",
          "1.0 (reference)"
        ],
        [
          "0–4",
          "2",
          "24.3 (0.73–811.0)",
          "3",
          "22.9 (7.7–68.6)",
          "3",
          "25.9 (16.9–39.7)",
          "5",
          "14.8 (9.8–22.3)"
        ],
        [
          "5–14",
          "2",
          "27.1 (17.5–54.1)",
          "3",
          "8.2 (2.3–29.4)",
          "3",
          "24.1 (16.9–34.4)",
          "5",
          "6.3 (2.9–13.7)"
        ],
        [
          "≥ 15",
          "1",
          "30.7 (17.5–54.1)",
          "2",
          "13.4 (9.5–18.8)",
          "1",
          "24.7 (14.2–43.0)",
          "3",
          "11.7 (7.6–18.0)"
        ]
      ],
      "notes": "[Transcriber: the header has three levels (baseline LTBI status > follow-up period > No. of studies / Risk ratio); the top two levels are combined in 'group' as '<status> – <follow-up>'.]",
      "narratives": {
        "en": "The table gives pooled risk ratios (with confidence intervals) and numbers of studies for progression to active TB among household contacts aged 0–4, 5–14 and ≥ 15 years, compared with the general population as reference. Estimates are shown for contacts who were LTBI-positive at baseline and for all contacts regardless of baseline LTBI status, at follow-up of under 12 and under 24 months.",
        "ar": "يعرض الجدول نسب الخطر المجمّعة (مع فترات الثقة) وعدد الدراسات بشأن التطور إلى السل النشط بين المخالطين المنزليين في الفئات العمرية 0–4 و5–14 و15 سنة فأكثر، مقارنة بعموم السكان كمرجع. وتُعرض التقديرات للمخالطين الإيجابيين لعدوى السل الكامنة عند خط الأساس ولجميع المخالطين بغض النظر عن حالة العدوى الكامنة عند خط الأساس، لفترات متابعة تقل عن 12 شهراً وعن 24 شهراً.",
        "zh": "本表给出0–4岁、5–14岁和≥15岁家庭接触者发展为活动性结核病的合并风险比（含置信区间）及研究数量，并以一般人群为参照。估计值分别针对基线时潜伏性结核感染阳性的接触者和不论基线感染状况的全部接触者，随访期为不足12个月和不足24个月。",
        "es": "El cuadro presenta los cocientes de riesgo agrupados (con intervalos de confianza) y el número de estudios sobre la progresión a tuberculosis activa en contactos domiciliarios de 0–4, 5–14 y ≥ 15 años, en comparación con la población general como referencia. Las estimaciones se muestran para los contactos con infección tuberculosa latente positiva al inicio y para todos los contactos con independencia de dicha condición, con seguimientos inferiores a 12 y a 24 meses.",
        "fr": "Le tableau présente les rapports de risque groupés (avec intervalles de confiance) et le nombre d’études concernant l’évolution vers une tuberculose évolutive chez les contacts familiaux âgés de 0–4, 5–14 et ≥ 15 ans, par rapport à la population générale prise comme référence. Les estimations portent sur les contacts positifs pour l’infection tuberculeuse latente au départ et sur l’ensemble des contacts quel que soit ce statut, pour des suivis de moins de 12 et de moins de 24 mois.",
        "ru": "В таблице приведены объединенные отношения рисков (с доверительными интервалами) и число исследований по прогрессированию до активного туберкулеза у бытовых контактов в возрасте 0–4, 5–14 и ≥ 15 лет по сравнению с общим населением в качестве референтной группы. Оценки даны для контактов с положительным результатом на латентную туберкулезную инфекцию на исходном уровне и для всех контактов независимо от исходного статуса, при сроках наблюдения менее 12 и менее 24 месяцев."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3. Recommended dosages of medicines for TB preventive treatment",
      "pages": [
        36
      ],
      "columns": [
        {
          "titles": "Regimen"
        },
        {
          "titles": "Dose by weight band"
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "6 or 9 months of daily isoniazid monotherapy (6H, 9H)",
          "Age 10 years & older: 5 mg/kg/day Age <10 years: 10 mg/kg/day (range, 7–15 mg)",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Four months of daily rifampicin (4R)",
          "Age 10 years & older: 10 mg/kg/day Age <10 years: 15 mg/kg/day (range, 10–20 mg)",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Three months of daily rifampicin plus isoniazid (3HR)",
          "Isoniazid: Age 10 years & older: 5 mg/kg/day Age <10 years: 10 mg/kg/day (range, 7–15 mg) Rifampicin: Age 10 years & older: 10 mg/kg/day Age <10 years: 15 mg/kg/day (range, 10–20 mg)",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Three months of rifapentine plus isoniazid weekly (12 doses) (3HP)",
          "Age 2–14 years",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "",
          "Medicine, formulation",
          "10–15 kg",
          "16–23 kg",
          "24–30 kg",
          "31–34 kg",
          ">34 kg"
        ],
        [
          "",
          "Isoniazid, 100 mg*",
          "3",
          "5",
          "6",
          "7",
          "7"
        ],
        [
          "",
          "Rifapentine, 150 mg",
          "2",
          "3",
          "4",
          "5",
          "5"
        ],
        [
          "",
          "Age >14 years",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "",
          "Medicine, formulation",
          "30–35 kg",
          "36–45 kg",
          "46–55 kg",
          "56–70 kg",
          ">70 kg"
        ],
        [
          "",
          "Isoniazid, 300 mg",
          "3",
          "3",
          "3",
          "3",
          "3"
        ],
        [
          "",
          "Rifapentine, 150 mg",
          "6",
          "6",
          "6",
          "6",
          "6"
        ],
        [
          "",
          "* 300mg formulation can be used to reduce pill burden",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "One month of rifapentine plus isoniazid daily (28 doses) (1HP)",
          "Age ≥13 years (regardless of weight band) Isoniazid, 300 mg/day Rifapentine, 600 mg/day",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Six months of levofloxacin daily (preventive treatment of MDR-TB)",
          "Age >14 years, by body weight: < 46 kg, 750 mg/day; >45 kg, 1g/day Age <15 years (range, approx. 15–20 mg/kg/day), by body weight: 5–9 kg: 150 mg/day; 10–15 kg: 200–300mg/day; 16–23 kg: 300–400mg/day; 24–34 kg: 500–750mg/day",
          "",
          "",
          "",
          "",
          ""
        ]
      ],
      "notes": "[Transcriber: the 'Dose by weight band' header spans columns B–G; the weight-band sub-tables nested in the 3HP row are laid out on columns B–G. The '* 300mg formulation…' footnote is printed inside the table, as body row 12.]",
      "narratives": {
        "en": "The table gives the recommended doses of medicines for each TB preventive treatment regimen (6H/9H, 4R, 3HR, 3HP, 1HP and six months of levofloxacin for MDR-TB contacts), by age and, where relevant, body weight. For 3HP it gives the number of isoniazid and rifapentine tablets per weight band for ages 2–14 years and over 14 years.",
        "ar": "يعرض الجدول الجرعات الموصى بها من الأدوية لكل نظام من نظم العلاج الوقائي من السل (6H/9H و4R و3HR و3HP و1HP وستة أشهر من الليفوفلوكساسين لمخالطي مرضى السل المقاوم للأدوية المتعددة)، حسب العمر، وحسب وزن الجسم عند الاقتضاء. وبالنسبة لنظام 3HP، يبيّن عدد أقراص الإيزونيازيد والريفابنتين لكل فئة وزن للأعمار من 2 إلى 14 سنة وما فوق 14 سنة.",
        "zh": "本表按年龄并在适用时按体重给出各结核病预防性治疗方案（6H/9H、4R、3HR、3HP、1HP以及用于耐多药结核病接触者的6个月左氧氟沙星）的推荐药物剂量。对于3HP，表中列出2–14岁和14岁以上各体重段所需的异烟肼和利福喷丁片数。",
        "es": "El cuadro indica las dosis recomendadas de los medicamentos para cada pauta de tratamiento preventivo de la tuberculosis (6H/9H, 4R, 3HR, 3HP, 1HP y seis meses de levofloxacino para contactos de TB-MDR), según la edad y, cuando procede, el peso corporal. Para 3HP indica el número de comprimidos de isoniazida y rifapentina por franja de peso para las edades de 2 a 14 años y de más de 14 años.",
        "fr": "Le tableau indique les doses recommandées de médicaments pour chaque schéma de traitement préventif de la tuberculose (6H/9H, 4R, 3HR, 3HP, 1HP et six mois de lévofloxacine pour les contacts de TB-MR), selon l’âge et, le cas échéant, le poids corporel. Pour le schéma 3HP, il précise le nombre de comprimés d’isoniazide et de rifapentine par tranche de poids pour les 2–14 ans et les plus de 14 ans.",
        "ru": "В таблице приведены рекомендуемые дозы препаратов для каждой схемы профилактического лечения туберкулеза (6H/9H, 4R, 3HR, 3HP, 1HP и шесть месяцев левофлоксацина для контактов больных МЛУ-ТБ) в зависимости от возраста и, где это применимо, массы тела. Для схемы 3HP указано число таблеток изониазида и рифапентина по весовым категориям для возраста 2–14 лет и старше 14 лет."
      },
      "csv": "tables/table-3.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 15,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 16,
      "note": "3 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 1
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 3
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p44); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p9); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 15,
      "note": "15 of 16 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-331170"
  }
}
